Valkre Solutions — Deal Memo
GS Lead · Series A Closed Jul 2025
V
Valkre Solutions, Inc.
Category-Defining Key Account Management (KAM) SaaS Platform
INVESTMENT
$5M
Series A · 3 Tranches
KAM SaaS
Bootstrapped → Funded
Gartner #1 KAM Platform
Delaware C-Corp
Founded 2017 · KAM Pivot 2020
ARR (2025E)
$3.0M
↑ 20%+ CAGR / 3yr
Net Retention
>100%
↑ Zero competitive churn
Gross Margin
~81%
↑ SaaS-grade margins
Customers
27
↑ 10,000+ users
Pre-Money Val.
$14.3M
4.5x ARR · QOE-based
FY25 ARR (Contracted)
$2.62M
27 customers · $97K avg ACV
↑ 29.9% YoY from FY24
Pipeline ACV
$6.3M
63 companies · $1.7M by Jan'26
300% pipeline increase
GS Ownership Target
~35%
Post-money · full $5M deployed
1x liq. pref + 8% div.
EBITDA Margin (FY25E)
~13%
Profitable at current scale
→ 37% by FY30 (Base)
Revenue Forecast — Base / Upside / Downside
FY25A → FY30E · GAAP ASC 606
| Metric | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E |
|---|
Customer Base (FY25)
| Customer | Vertical | FY25 ARR | % Total | Status |
|---|---|---|---|---|
| Pfizer | Pharma | $550K | 21.0% | |
| BeiGene | Pharma | $200K | 7.6% | |
| Boehringer Ingelheim | Pharma | $300K | 11.4% | ↓ Contracting |
| Forrester | Technology | $198K | 7.6% | |
| Ecolab | Industrial | $183K | 7.0% | |
| Lowe's | Retail | $150K | 5.7% | = Stable |
| Cuna Mutual | Financial | $135K | 5.1% | = Stable |
| EMD-Serono | Pharma | $125K | 4.8% | = Stable |
| UL Solutions | Technology | $114K | 4.3% | = Stable |
| Wabash | Industrial | $82K | 3.1% | |
| + 17 others | — | $585K | 22.3% | — |
| TOTAL (27 customers) | $2.62M | 100% |
Unit Economics
| Avg ACV / Customer | $97K |
| Net Revenue Retention | >100% |
| Gross Margin | ~81% |
| Annual Churn Rate | ~2% |
| NRR (FY26E proj.) | 112% |
| Pipeline / ARR Ratio | 2.4x |
| Rev Mix: Software | 85% |
| Rev Mix: Services | 15% |
| Billing: Annual | 22 / 27 |
| Billing: Quarterly | 5 / 27 |
Revenue Concentration
⚠ Concentration risk: Top 3 = 40% of ARR. Pfizer potential global expansion is upside + risk. Recommend multi-year lock-in.
Revenue by Vertical (FY25)
ARR Growth Trajectory
Investment Thesis
Category-Defining Platform: Gartner created the "Account Planning Tool" category in 2023 with Valkre as the most complete solution. No lost competitive RFPs — all churn from business exits, never product failure.
Capital Efficiency: Bootstrapped to $3M ARR with <$5M raised in 8 years. Profitable/breakeven at current scale. Demonstrates extreme capital discipline and product-market fit validation without VC subsidy.
Land & Expand Flywheel: Multiple customers expanding from 1 BU to multi-BU (Pfizer: 4 US BUs → global; Lowe's: $50K → $150K; BeiGene: $50K → $200K). NRR >100% with 3-year contracts being signed.
GenAI Moat in Development: Proprietary KAM data trapped in Valkre is uniquely valuable for AI insights. Pilots live with Boehringer Ingelheim — turns Valkre into a strategic data platform, not just workflow software.
Strategic Distribution: ZS Associates (pharma sales consultancy) and SAMA (global KAM association) provide warm introductions into pharma and industrials — channels competitors cannot replicate easily.
Large, Underserved TAM: ~1M KAM professionals globally still using PPT/Excel. $1.75B company-based TAM in industrials + pharma alone. Market inflection driven by demographic shift (younger KAMs demand tech) and B2B model evolution.
Risk Assessment
HIGH
Customer Concentration: Pfizer = 21% of ARR. Boehringer = 11.4%. Top 3 customers = ~40% of total ARR. Any single loss would be materially damaging. Mitigated by multi-year contracts and global expansion discussions, but remains key risk.
HIGH
Founder-Centric GTM: Jerry Alderman has been the primary sales driver. Formal sales engine only initiated in late 2023. Pipeline has grown 300% but repeatability of non-founder-led sales is unproven at scale.
MED
Vertical Concentration: Pharma (~50%) and Industrials (~35%) dominate the book. Downturn in either sector (pharma M&A consolidation, industrial capex cuts) could cascade across customer base simultaneously.
MED
Team Capacity: 14 employees serving 27 enterprise customers with complex implementations. Scaling from $3M to $10M ARR requires significant hiring in CS, engineering, and sales — execution risk in a competitive talent market.
LOW
Competitive Displacement: Salesforce, Microsoft, or Veeva could build native KAM modules. However, zero competitive RFP losses to date, Gartner validation, and deep process tuning create a meaningful defensive moat.
LOW
High ACV / Long Sales Cycle: $97K average ACV with enterprise procurement processes. Could limit velocity of new logo growth. Partially mitigated by strong referral channel and SAMA/ZS network effect.
Deal Terms (Signed Jul 2025)
Investment Amount
$5,000,000
Security Type
Series A Preferred
Lead Investor
Golden Section
Structure
3 Equal Tranches
Pre-Money Valuation
$14.3M (4.5x ARR)
GS Ownership (Post)
~35%
Liquidation Preference
1x + Accrued Divs
Dividend
8% Cumulative
Dividend Compounding
1-Year
Board Seats
5 (2 GS, 2 Founders, 1 Ind.)
Exit Multiple
8x Revenue
Closing Date
90 Days from Execution
P&L Bridge: Cash vs GAAP
| Metric | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|
| Cash Collections | $2.68M | $3.64M | $5.00M | $6.15M |
| GAAP Revenue | $2.66M | $3.53M | $4.93M | $6.08M |
| Gross Profit | $2.15M | $2.75M | $3.84M | $4.74M |
| Gross Margin % | 81% | 78% | 78% | 78% |
| EBITDA | $346K | $458K | $1.08M | $1.76M |
| EBITDA Margin | 13% | 13% | 22% | 29% |
| Deferred Revenue Bal. | $1.60M | $1.72M | $1.79M | $1.86M |
Key note: Annual billers create Q1 cash bulge vs ratable GAAP recognition. Deferred revenue balance of ~$1.6M provides visibility. 78% gross margin reflects SaaS hosting + light implementation.
Exit Analysis & Return Scenarios
8x revenue exit multiple · GS ~35% ownership · $5M invested
Base Case Exit (FY28)
$48.6M
EV at 8x $6.1M GAAP rev
GS proceeds: ~$17M · 3.4x MOIC
Upside Exit (FY28)
$57.9M
EV at 8x $7.2M GAAP rev
GS proceeds: ~$20M · 4.0x MOIC
Downside Exit (FY28)
$30.2M
EV at 8x $3.8M GAAP rev
GS proceeds: ~$11M · 2.2x MOIC
Potential Strategic Acquirers
Salesforce (CRM augmentation)
Microsoft (Teams + CRM)
Veeva Systems (life sciences)
IQVIA (pharma SaaS)
SAP / Oracle (account planning)
PE rollup (vertical SaaS)
ZS Associates (tech-enabled services)
Founder & Team
JA
Jerry Alderman
CEO & Co-Founder
Deep enterprise relationships in KAM ecosystem. Primary sales driver and thought leader — presenting at SAMA conferences alongside Pfizer. Pivoted company to KAM in 2020 after years of co-creation with large enterprise clients.
BK
Brian Kiep
COO & Co-Founder
Operational leader managing product, implementation, and customer success. Co-architected the KAM platform with enterprise customer feedback. Manages the 14-person team and enterprise deployment playbook.
Team: 14 employees. Lean but capable. Key hire needs: VP Sales, 2 AEs, 2 engineers, 1 CS lead (FY26 plan). GS board seat provides hiring network access.
Market Context
| TAM (Industrials) | ~$1.5B |
| TAM (Pharma / HC) | ~$250M |
| Total Addressable Market | ~$1.75B |
| KAM Programs (Industrial) | 12,000+ |
| KAM Professionals (Global) | >1,000,000 |
| Still Using PPT/Excel | >90% |
| Gartner Category | Account Planning Tool |
| Valkre Gartner Rank | #1 Most Complete |
Market timing: CRM was defined in the 1990s for transactional selling. KAM requires team-based, relationship-focused, multi-stakeholder coordination. GenAI is creating the next forcing function — Valkre's structured data is uniquely positioned to unlock AI value.
GP Recommendation: INVEST — Lead $5M Series A
Valkre represents a rare combination of category leadership, capital efficiency, exceptional customer retention, and strong unit economics in an emerging, large market. The transition from PPT/Excel to purpose-built KAM software is inevitable — Valkre is the Gartner-validated leader with no competitive churn, 100%+ NRR, and blue-chip enterprise logos. At 4.5x ARR with 3-tranche structure, the entry valuation is reasonable. The $5M capital infusion funds a repeatable sales engine to drive $3M → $10M+ ARR over 2-3 years.
Use of Funds
• 2 AEs + 1 VP Sales
• 2 engineers (AI roadmap)
• Marketing investment
• CS & implementation
• 2 engineers (AI roadmap)
• Marketing investment
• CS & implementation
Key Milestones
• $1.7M new ARR by Jan'26
• SOC 2 maintained
• Pfizer global expansion
• AI feature launch FY26
• SOC 2 maintained
• Pfizer global expansion
• AI feature launch FY26
GS Value-Add
• Board seat + operator network
• B2B SaaS GTM playbooks
• Enterprise customer intros
• M&A / exit advisory
• B2B SaaS GTM playbooks
• Enterprise customer intros
• M&A / exit advisory
Derek AI
Valkre Deal Intelligence
Valkre · Series A